Displaying 1 - 4 of 4
| Active Ingredient | BICTEGRAVIR | EMTRICITABINE | TENOFOVIR |
| Therapeutic Class | ANTIRETROVIRALS MISCELLANEOUS |
| Indications | HIV infection. |
| Caution | Patients with HIV-1 infection should be tested for the presence of chronic hepatitis B virus (HBV) before initiating antiretroviral therapy (ART)Lactic acidosis and severe hepatomegaly with steatosis, More ... |
| Dose Range | One tablet once daily on an empty stomach; not recommended for pediatric patients younger than 18 years. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | COBICSTAT | ELVITEGRAVIR | EMTRICITABINE | TENOFOVIR |
| Therapeutic Class | ANTIRETROVIRALS MISCELLANEOUS |
| Indications | HIV Infection |
| Caution | Appetite decreased; asthenia; constipation; diarrhoea; dizziness; electrolyte imbalance; flatulence; gastrointestinal discomfort; headache; hyperbilirubinaemia; hyperglycaemia; hypersensitivity; hyper More ... |
| Dose Range | 1 tablet once daily. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | EFAVIRENZ | EMTRICITABINE | TENOFOVIR |
| Therapeutic Class | ANTIRETROVIRALS MISCELLANEOUS |
| Indications | HIV infection |
| Caution | Lactic acidosis and severe hep atomegaly with steatosis, including fatal cases, have been rep orted with the use of nucleoside analogues in combination with other antiretrovirals. |
| Dose Range | One tablet once daily on an empty stomach; not recommended for pediatric patients younger than 18 years. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | EMTRICITABINE | TENOFOVIR |
| Therapeutic Class | ANTIRETROVIRALS MISCELLANEOUS |
| Indications |
Indicated in combination ,with other antiretroviral agents (ARTs) for treatment of HIV-1 infection in adults. HIV-1 Pre-exposure Prophylaxis Indicated for at-risk patients to reduce risk of HIV-1 More ... |
| Caution | Lactic acidosis and severe hepatomegaly with steatosis. Emtricitabine/tenofovir should not be used as part of a triple nucleoside regimen. Emtricitabine/ tenofovir should not be coadministered with it More ... |
| Dose Range | One tablet once daily with or without food; not recommended for pediatric patients younger than 18 years |
| Drug Interactions | Concomitant use of emtricitabine/tenofovir DF (FTC/TDF) with certain drugs may result in known or potentially clinically important drug interactions, some of which may increase plasma concentrations o More ... |
| Pregnancy | |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |